MOZART: IVUS reduces contrast volume needed for angioplasty

Contrast nephropathy is associated with increased morbidity and so this study evaluates the possibility of reducing the required necessary volume of contrast  using coronary intravascular ultrasound (IVUS). Patients were randomized to IVUS  guided angioplasty (n = 41) and angiography guided angioplasty (n = 42). IVUS-guided angioplasty requires a smaller volume of contrast (22.9 ± 12.5 ml versus 71.4 ± 35.9 ml, p <0.001). There was a lengthy procedure using IVUS but that did not affect the radiation dose or fluoroscopy time. In patients at high risk of contrast nephropathy IVUS use must be considered.

Pedro Lemos
2013-10-31

Original title: IVUS Guidance During PCI to Reduce Contrast Use. The MOZART randomized trial

More articles by this author

TRANSLATE-POPS: Routine measurement of platelet aggregation generates a minimal impact on the treatment setting

The high platelet reactivity is associated with adverse events after stent implantation. Current guidelines consider the measurement of aggregability as a class IIB and...

TATORT-NSTEMI: Routinely thromboaspiration in patients with non ST-elevation AMI

Thromboaspiration in patients with ST-elevation is being questioned while in patients without elevation this strategy has not been studied. The study included 440 patients...

REPRISE II: LOTUS valve for percutaneous aortic valve replacement

The aim of this study was to evaluate the safety and efficacy of the new device in patients with severe aortic stenosis at high...

GIANT: Evaluation of the genetic profile of CYP2C19 in patients undergoing primary angioplasty

The aim of this study was to evaluate the clinical impact resistance thienopyridines through genetic analysis of CYP2C19 receptor. The primary endpoint was  a...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long-Term Predictors of Valve Deterioration After TAVI

Transcatheter aortic valve implantation (TAVI) has become an innovative technology for the treatment of patients with severe aortic valve stenosis. Initially implemented in elderly...

Coronary access after TAVI with fourth- and fifth-generation Evolut valves: the EPROMPT-CA study

The expansion of transcatheter aortic valve implantation (TAVI) toward younger and lower-risk patients has increased the relevance of post-procedural coronary access. In this context,...

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...